II. Indications
- HIV Infection in either Antiretroviral naive or experienced patients (combination therapy)
III. Contraindications
- Creatinine Clearance <30 ml/min and use of a strong CYP3A4 inhibitor or inducer
IV. Mechanism
V. Medications: Maraviroc
- Tabs: 25, 75, 150 and 300 mg
- Solution: 20 mg/ml
VI. Dosing: Adult
- Strong CYP3A4 Inhibitors (e.g. Clarithromycin, Itraconazole, most HIV Protease Inhibitors except Tipranavir/r)
- Take 150 mg orally twice daily
- Avoid if Creatinine Clearance <30 ml/min
- Insignificant CYP3A4 Effects (e.g. nRTIs, Nevirapine, Raltegravir, Tipranavir/r)
- Take 300 mg orally twice daily
- Strong CYP3A4 Inducers (e.g. Carbamazepine, Efavirenz, Etravirine, Phenobarbital, Phenytoin, Rifampin)
- Take 600 mg orally twice daily
- Avoid if Creatinine Clearance <30 ml/min
VII. Dosing: Child (age >2 years, weight >=10 kg)
- Strong CYP3A4 Inhibitors (e.g. Clarithromycin, Itraconazole, most HIV Protease Inhibitors except Tipranavir/r)
- Weight 10 to 20 kg: Give 50 mg orally twice daily
- Weight 20 to 30 kg: Give 75 mg orally twice daily
- Weight 30 to 40 kg: Give 100 mg orally twice daily
- Weight >40 kg: Give 150 mg orally twice daily (adult dose)
- Avoid if Creatinine Clearance <30 ml/min
- Insignificant CYP3A4 Effects (e.g. nRTIs, Nevirapine, Raltegravir, Tipranavir/r)
- Weight >=30 kg: Give 300 mg orally twice daily (adult dose)
- Strong CYP3A4 Inducers (e.g. Carbamazepine, Efavirenz, Etravirine, Phenobarbital, Phenytoin, Rifampin)
- Avoid Maraviroc in children with concurrent use of strong CYP3A4 inducers
VIII. Adverse Effects
- Well tolerated overall
- Fever
- Upper respiratory symptoms (e.g. cough, Bronchitis)
- Abdominal Pain
-
Orthostatic Hypotension
- More common with Renal Insufficiency
- Myalgia
- Increased Myocardial Infarction risk
-
Hypersensitivity Rash
- DRESS Syndrome risk (rash and Eosinophilia)
- May be associated with hepatoxicity
- Stop Maraviroc immediately for signs of Hypersensitivity
- Hepatotoxicity
- Higher risk if comorbid Hepatitis B or Hepatitis CVirus infection
- Comorbid hepatic Impairment (esp. with strong CYP3A4 Inhibitor use) also increases other adverse effects
- May be associated with DRESS Syndrome
- Liver Function Tests baseline and periodically
- Stop Maraviroc immediately for signs of hepatotoxicity
IX. Drug Interactions
- Maraviroc is a substrate of CYP3A4 and very sensitive to the enzyme's activity (see dosing above)
- Contraindicated agents with Maraviroc
- Unboosted Fosamprenavir
- St Johns Wort
X. Resources
XI. References
- (2007) Presc Lett, New Drug: Maraviroc, Resource #230904
- (2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
- Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
selzentry (on 1/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
SELZENTRY 150 MG TABLET | $26.39 each | |
SELZENTRY 300 MG TABLET | $26.46 each |